Kyowa Hakko Kirin To Submit NDA For ATL Drug Without Phase III Study
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin is planning to skip final stage Phase III trials and submit a new drug application for KW-0761 next spring in Japan